HER2-Positive

This section is for HER2-positive breast-cancer topics that need their own treatment and resistance context.

It focuses on regimen-specific summaries, progression questions, biomarker interpretation, and adjunctive considerations that are specific to HER2-positive disease rather than breast cancer in general.

Start here

• HER2CLIMB

• Enhertu, Senescence, and the Senolytic Second Strike — how trastuzumab deruxtecan can leave behind senescent or dormant tumour cells, and why post-cycle clean-up timing is being discussed

• Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin? — short practical answer for the HER2+/ERα+ caution

• HER2+ Breast Cancer – Integrative Protocols

• Support Threads & Docs

Key caution pairing

These two pages work together.

Use the first for the direct answer.

Use the second for the deeper mechanism and evidence limits.

• Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin? — practical answer first

• HER2+ Cancers — deeper polydatin, resveratrol, and Δ16HER2 context

This section can expand to include

• early-stage vs metastatic context

• resistance pathways beyond HER2CLIMB

• subtype-specific side effects and supportive care

• testing and monitoring questions

• adjunctive and CAM summaries for HER2-positive settings